Evidence map›Paper›PMID 42658319›Full record

ArticleNeurogenetics2026

Significant differences in phenotype and age of onset in an SPG4 family caused by whole SPAST deletion combined with a hemizygous S44L modifier.

Jana Vasova, Cinzia Rinaldo, Francesca Sardina, Anna Peckova, Ladislava Rennerova, Dana Safka Brozkova, Alena Musilova, Anna Uhrova Meszarosova

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Neurogenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jana VasovaNeurogenetic Laboratory, Department of Paediatric Neurology, Second Faculty of Medicine, Charles University, Motol and Homolka University Hospital, Prague, Czech Republic.ORCID http://orcid.org/0009-0002-9864-1852
Cinzia RinaldoInstitute of Molecular Biology and Pathology, National Research Council, Rome, Italy.
Francesca SardinaInstitute of Molecular Biology and Pathology, National Research Council, Rome, Italy.
Anna PeckovaDepartment of Medical Genetics, Masaryk Hospital in Usti nad Labem, Usti nad Labem, Czech Republic.
Ladislava RennerovaDepartment of Paediatric Neurology, Masaryk Hospital in Usti nad Labem, Usti nad Labem, Czech Republic.
Dana Safka BrozkovaNeurogenetic Laboratory, Department of Paediatric Neurology, Second Faculty of Medicine, Charles University, Motol and Homolka University Hospital, Prague, Czech Republic.
Alena MusilovaNeurogenetic Laboratory, Department of Paediatric Neurology, Second Faculty of Medicine, Charles University, Motol and Homolka University Hospital, Prague, Czech Republic.
Anna Uhrova MeszarosovaNeurogenetic Laboratory, Department of Paediatric Neurology, Second Faculty of Medicine, Charles University, Motol and Homolka University Hospital, Prague, Czech Republic. anna.meszarosova@lfmotol.cuni.cz.

Funding

Ministerstvo Zdravotnictví Ceské Republiky 00064203Ministerstvo Zdravotnictví Ceské Republiky NU22-04-00097NextGenerationEU LX22NPO5107
6 · The paper itself

Abstract

Hereditary spastic paraplegia type 4 (SPG4) is a neurodegenerative disorder with variable age of onset and severity. We report a patient with early-onset SPG4 resulting from compound heterozygosity for a full-gene SPAST deletion and partial DPY30 loss, together with the hemizygous NM_014946.6(SPAST):c.131 C > T p.(Ser44Leu) variant. Western blot showed a similar reduction in the M87 spastin isoform in all deletion-carrying relatives, including the proband, indicating that this reduction alone does not explain the marked difference in phenotype severity: relatives had mild symptoms, whereas the proband had an early-onset, severe phenotype. This co-occurrence of a whole-SPAST deletion, partial DPY30 loss, and a hemizygous phenotype-modifier variant in one individual has, to our knowledge, not been previously reported. We hypothesise that the p.(Ser44Leu)-modified spastin may add to the effect of SPAST haploinsufficiency to produce the more severe phenotype, though the precise mechanism remains unconfirmed.

Indexed as

Adenosine TriphosphatasesSpastic Paraplegia, HereditarySpastinAdolescentAdultAge of OnsetChildFemaleGene DeletionHaploinsufficiencyHemizygoteHumansMaleMiddle AgedParaplegiaPedigreeAdenosine TriphosphatasesSpastinSPAST protein, humanDominant-negative effectHaploinsufficiencyHereditary spastic paraplegiaPhenotype modifierSPAST gene

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.